63590-64-7

63590-64-7 structure

Name: Terazosin
Chemical Name: terazosin
CAS Number: 63590-64-7
Molecular Formula: C₁₉H₂₅N₅O₄
Molecular Weight: 387.43300
Catalog: API Circulatory system medication Antihypertensive drug
Create Date: 2018-08-29 08:00:37
Modify Date: 2024-01-02 13:01:09
Terazosin is a selective alpha1-antagonist used for treatment of symptoms of benign prostatic hyperplasia (BPH).Target: Alpha-1 Adrenergic ReceptorTerazosin is selective for alpha 1A-adrenoceptors which appear to dominate in the human prostate; the therapeutic relevance of this selectivity remains to be assessed in clinical studies [1]. Administration of terazosin 1 mg orally for 28 d. Terazosin initially shifted the dose-response curve of phenylephrine to the right, with a significant increase in ED50 for phenylephrine from a control value of 102 to 759 ng/min on day 1 of terazosin (P < 0.001). The mean Kd of terazosin was estimated as 11 +/- 15 nM in the first few days of treatment. This study demonstrates that pharmacological tolerance to the alpha 1-adrenoceptor blocking action of terazosin occurs in man and may be responsible for loss in efficacy with chronic therapy [2].

Name	terazosin
Synonyms	Terazosin Hydrochloride [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(oxolan-2-yl)methanone MFCD00467965

Description	Terazosin is a selective alpha1-antagonist used for treatment of symptoms of benign prostatic hyperplasia (BPH).Target: Alpha-1 Adrenergic ReceptorTerazosin is selective for alpha 1A-adrenoceptors which appear to dominate in the human prostate; the therapeutic relevance of this selectivity remains to be assessed in clinical studies [1]. Administration of terazosin 1 mg orally for 28 d. Terazosin initially shifted the dose-response curve of phenylephrine to the right, with a significant increase in ED50 for phenylephrine from a control value of 102 to 759 ng/min on day 1 of terazosin (P < 0.001). The mean Kd of terazosin was estimated as 11 +/- 15 nM in the first few days of treatment. This study demonstrates that pharmacological tolerance to the alpha 1-adrenoceptor blocking action of terazosin occurs in man and may be responsible for loss in efficacy with chronic therapy [2].
Related Catalog	Signaling Pathways >> GPCR/G Protein >> Adrenergic Receptor Natural Products >> Alkaloid Research Areas >> Metabolic Disease
References	[1]. Michel, M.C., et al., Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned alpha 1-adrenoceptor subtypes and in human prostate. J Auton Pharmacol, 1996. 16(1): p. 21-8. [2]. Vincent, J., et al., Pharmacological tolerance to alpha 1-adrenergic receptor antagonism mediated by terazosin in humans. J Clin Invest, 1992. 90(5): p. 1763-8.

CHEMICAL NAME :: Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-((tetrahyd ro-2-furanyl)carbonyl )-

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: USXXAM United States Patent Document. (U.S. Patent Office, Box 9, Washington, DC 20231) Volume(issue)/page/year: #4734418

Symbol	GHS07
Signal Word	Warning
Hazard Statements	H302
Personal Protective Equipment	dust mask type N95 (US);Eyeshields;Gloves
Hazard Codes	Xn: Harmful;
Risk Phrases	R22
Safety Phrases	S26
RIDADR	NONH for all modes of transport
WGK Germany	3
RTECS	TK8044925

943644-21-1

63590-64-7

Literature: US2007/161791 A1, ; Page/Page column 2; 3-4 ;

23680-84-4

63074-07-7

63590-64-7

Literature: US6313293 B1, ;

19237-84-4

63590-64-7

Precursor 3
23680-84-4 63074-07-7 19237-84-4
DownStream 0